| Date | Title | Description |
| 12.01.2026 | Qureight appoints Rebecca Simmons as Chief Operating Officer | - |
| 07.01.2026 | Qureight appoints Dr Steven Bishop as Chief Medical Officer | - |
| 27.10.2025 | Qureight Vascul8 model for pulmonary vascular disorders validated in peer-reviewed study, offering potential to improve treatment options and patient outcomes following surgery | - |
| 01.09.2025 | Qureight appoints Craig Rhodes as Head of Partnerships to lead on pharma relationship management | - |
| 15.07.2025 | Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion | - |
| 22.04.2024 | Qureight Raises $8.5M in Series A Funding | Qureight, a Cambridge, UK-based biotech company providing a drug development platform, raised $8.5M in Series A funding.
The round was led by Hargreave Hale AIM VCT with participation from XTX Ventures, Guinness Ventures, Playfair Capital, ... |
| 18.04.2024 | Qureight Revolutionizes Clinical Trial Imaging with $8.5M Funding | Qureight, a biotech company based in Cambridge, UK, has secured a whopping $8.5 million in their Series A funding round. Founded in 2018, Qureight is on a mission to transform clinical trial imaging analysis and data curation for lung and h... |
| 16.04.2024 | Cambridge-based Qureight raises €8 million Series A to accelerate drug development in lung and heart disease | - |
| 15.04.2024 | Qureight raises $8.5M for clinical trial imaging to accelerate drug development | Biotech company Qureight has today announced the close of their significantly oversubscribed $8.5 million Series A round.
Founded in 2018 and headquartered in Cambridge, UK, Qureight initially targets clinical trial imaging analysis and dat... |
| 12.01.2024 | Qureight founder: Pitching to investors is energising once you take the plunge | - |
| 04.02.2022 | Annual #21toWatch announces shortlist in advance of return to in-person awards event | Annual #21toWatch announces shortlist in advance of return to in-person awards event
04-02-2022
Next month’s coveted #21toWatch Awards announces 2022 shortlist, featuring some of the most ground-breaking entrepreneurs, startups and innovati... |
| 04.02.2022 | Annual #21toWatch announces shortlist in advance of return to in-person awards event | Next month’s coveted #21toWatch Awards announces 2022 shortlist, featuring some of the most ground-breaking entrepreneurs, startups and innovations from the East of England.
After presenting the Top21 awards virtually for the last two years... |
| 02.02.2022 | Qureight Raises £1.5M in Seed Funding | Qureight, a Cambridge, UK-based data company focusing on complex diseases, raised £1.5m in seed funding.
The round was led by Playfair Capital, with participation from Life Sciences funds Meltwind, Ascension and Cambridge Angels.
The compan... |
| 01.02.2022 | Cambridge-based Qureight raises £1.5 million to curate collection of complex disease data | - |
| - | Cambridge-based Qureight raises £1.5 million to curate collection of complex disease data | Cambridge-based data company Qureight has raised £1.5 million seed funding to deliver the next generation of its ground-breaking platform and capitalise on its vision to house the world’s largest collection of data from complex diseases. Th... |
| - | Qureight | “Qureight accelerates clinical trial development at key decision points through data curation and AI-powered decision making. We work with pharmaceutical companies, contract research organisations and hospitals to curate data and help the b... |
